Cisplatin
- TRADE NAMES: Cisplatyl; Plasticin; Platiblastin; Platinex; Platinol (Bristol-Myers Squibb); Platinol-AQ; Platistil
- INDICATIONS: Carcinomas, lymphomas
- SYNONYM: CDDP
- CLASS: Alkylating agent, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Platinum-based antineoplastic
- HALF-LIFE: alpha phase: 25–49 minutes; beta phase: 58–73 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aldesleukin, Atenolol, Chlorothiazide, Gadobenate, Methotrexate, Paclitaxel, Pentamidine, Rituximab, Selenium, Thalidomide, Torsemide, Torsemide, Trilaciclib, Zinc
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 10/12/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
